Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery
Kashiwagi, S.; Ishihara, S.; Ishii, M.; Asano, Y.; Watanabe, M.; Morisaki, T.; Aomatsu, N.; Noda, S.; Kawajiri, H.; Nakano, T.; Kawakami, N.; Mitsukawa, Y.; Takashima, T.; Onoda, N.; Ishikawa, T.; Hirakawa, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(12): 2384-2386
2013
ISSN/ISBN: 0385-0684 PMID: 24394120 Document Number: 668046
A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.